Atrix/Faulding enter deal for Leuprogel Depot
Atrix Laboratories has signed an exclusive agreement with FauldingPharmaceutical giving the latter Australian and New Zealand marketing rights to its three Leuprogel Depot (leuprolide acetate) products; one-, three- and four-month sustained-release injection, which utilizes the Atrigel depot drug delivery system, as a treatment for advanced prostate cancer. The Australian market for these types of products is currently over A$30 million ($15.5 million) annually.
Atrix recently signed an exclusive European marketing deal with MediGene licensing the rights for Leuprogel (Marketletter April 16), and has also applied for US Food and Drug Administration approval of the one-month formulation, with a filing for the three-month version expected later this year (Marketletter April 2). The company says it now has access to a substantial share of the global market for hormone treatments for prostate cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze